Form 4: Tenaya Therapeutics Director, Deepak Srivastava, Acquires 34,000 Stock Options

Director Deepak Srivastava acquired 34,000 stock options in Tenaya Therapeutics, Inc. on October 18, 2024, according to a Form 4 filing.

Summary

• Deepak Srivastava, a director of Tenaya Therapeutics, Inc. (TNYA), acquired 34,000 stock options on October 18, 2024.
• The options have an exercise price of $2.04.
• The options were granted under the company's 2021 Equity Incentive Plan.
• The options will vest in full on May 31, 2025, or earlier if the next annual meeting of stockholders occurs before that date, contingent on continued service to the Issuer.
• The expiration date for the options is October 17, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard insider transaction filing, indicating routine compensation practices. The acquisition of options by a director can be seen as a slightly positive signal, but it's not a major event.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where equity compensation is a standard practice.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates